FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Gunderson Robert V JR					2. Issuer Name <b>and</b> Ticker or Trading Symbol Theravance Biopharma, Inc. [TBPH]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last)	,	,	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/03/2014							X Director Officer (give title below)		Other (s below)				
GUNDERSON DETTMER STOUGH 1200 SEAPORT BLVD				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) REDWC	OOD C	<b>A</b> 9	94063	_										filed by One filed by More				
(City)	(St	ate) (	Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day				Execution Date,			Transaction Dispose Code (Instr. and 5)		curities Acquired (, sed Of (D) (Instr. 3 )		Securit Benefit Owned	ties cially	6. Owners Form: Dir (D) or Indirect (	ect	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amoun	Amount (A) or (D)				(Instr. 4)		(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	I. Title of 2. 3. Transaction Date Execution Date, or Exercise (Month/Day/Year)			Code (In	ransaction of ode (Instr. Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year) Amount of Securities Underlying Derivative Security (Instr. and 4)				of s ng e	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form Direct or In (I) (Ir 4)	t (D) direct	Beneficial Ownership	
				Code	v	(A)	(D)	Date Exercisable		piration ate	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$23.51	06/03/2014		A		12,000		(1)	06	5/02/2024	Common Stock	12,000	\$0	12,000		D		
Stock Option (Right to Buy)	\$23.51	06/03/2014		A		12,000		(2)	06	5/02/2024	Common Stock	12,000	\$0	12,000		D		

## Explanation of Responses:

- 1. This option may be exercised and shall be vested as to 1/36th of the shares subject to this option when optionee completes each continuous month of service following the grant date.
- 2. This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.

Brett A. Grimaud, Attorney-in-Fact 06/05/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.